<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363403">
  <stage>Registered</stage>
  <submitdate>17/12/2012</submitdate>
  <approvaldate>18/12/2012</approvaldate>
  <actrnumber>ACTRN12612001310853</actrnumber>
  <trial_identification>
    <studytitle>The Effectiveness of Intravitreal Aflibercept Treatment on Exudative Age-related Macular Degeneration Patients</studytitle>
    <scientifictitle>Obervational Study on the Effectiveness of Intravitreal Aflibercept in Exudative Age-related Macular Degeneration Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Exudative age-related macular degeneration </healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study is to evaluate the effectiveness of individualized intravitreal aflibercept in the treatment of exudative age-related macular degeneration (AMD) in routine clinical practice. Patients with previously or currently being treated with, or initiating treatment with intravitreal aflibercept for exudative AMD will be observed up to 24 months. Best corrected visual acuity and optical coherence tomography measurements will be collected at each visit if data are available.</interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Best-corrected visual acuity will be tested by snellen visual acuity chart or Early Treatment Diabetic Retinopathy Study (ETDRS) eye Charts. The patients will be asked to read letters from the top of the chart to the bottom, and the visual acuity is scored by how many letters could be correctly identified.</outcome>
      <timepoint>2 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Macular thickness will be measured by optical coherence tomography</outcome>
      <timepoint>2 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All adverse events,including study treatment related (Including eye pain, floater, irritation and haemorrhage, etc.) or unrelated  (including stroke, heart attack and pneumonia, etc), will be recorded during the 24 months follow up.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1) Previously or currently being treated with, or initiating treatment, with aflibercept for exudative AMD; and
2) Ability to provide informed consent and complete study assessments  </inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy or lactation
Premenopausal women not using contraception
Prior anti-VEGF injection in the study eye within 28 days of baseline
Prior treatment with photo dynamic therapy (PDT) within 90 days of baseline and more than 6 prior PDT treatments
Significant subretinal fibrosis or atrophy
Prior treatment with triamcinolone in the study eye within 6 months of baseline
Intraocular surgery in the study eye within 2 months of baseline
Simultaneous participation in a study that includes administration of any investigational drug or procedures.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>21/01/2013</anticipatedstartdate>
    <actualstartdate>31/01/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>28/11/2014</actualenddate>
    <samplesize>200</samplesize>
    <actualsamplesize>184</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>28/02/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Sydney Retina Clinic &amp; Day Surgery - Sydney</hospital>
    <postcode>2000 - Parliament House</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sydney Retina Clinic and Day Surgery</primarysponsorname>
    <primarysponsoraddress>Level 13, 187 Macquarie Street, Sydney, NSW 2000 Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Sydney Retina Clinic and Day Surgery</fundingname>
      <fundingaddress>Level 13, 187 Macquarie Street, Sydney, NSW 2000 Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed as an observational study on patients being treated with 2.0mg intravitreal aflibercept for exudative age-related macular degeneration in a tertiary retinal clinic. This study does not direct therapy or recommend any treatment other than that the patients be treated in accordance with the aflibercept local product label. Efficacy of the individualized intravitreal aflibercept will be assessed by the changes in bested corrected visual acuity and macular thickness measured by optical coherence tomography, which are the routine eye examinations for monitoring this type of disease. Timing of actual patients visits is at the discretion of the treating physician.
The study will be conducted for 30 months with a 6-month recruitment period and 24-month follow up period. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bellberry Ethics Committee</ethicname>
      <ethicaddress>229 Greenhill Road
 Dulwich
 South Australia 5065</ethicaddress>
      <ethicapprovaldate>30/01/2013</ethicapprovaldate>
      <hrec>2012-11-1204</hrec>
      <ethicsubmitdate>12/12/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Andrew Chang</name>
      <address>Level 13, 187 Macquarie Street, Sydney, NSW 2000 Australia</address>
      <phone>+61 2 9221 3755</phone>
      <fax />
      <email>achang@sydneyretina.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Andrew Chang</name>
      <address>Level 13, 187 Macquarie Street, Sydney, NSW 2000 Australia</address>
      <phone>+61 2 9221 3755</phone>
      <fax />
      <email>achang@sydneyretina.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Andrew Chang</name>
      <address>Level 13, 187 Macquarie Street, Sydney, NSW 2000 Australia</address>
      <phone>+61 2 9221 3755</phone>
      <fax />
      <email>achang@sydneyretina.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Andrew Chang</name>
      <address>Level 13, 187 Macquarie Street, Sydney, NSW 2000 Australia</address>
      <phone>+61 2 9221 3755</phone>
      <fax />
      <email>achang@sydneyretina.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>